eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.: "fremanezumab for the preventive treatment of chronic migraine."
.
he added: �these findings show that despite the tireless work of doctors and nurses, it appears that some cancer patients are still enduring shockingly long waits to start treatment.
.favorites
.
favorites
.